Regeneron price target raised to $1,082 from $1,055 at BMO Capital

BMO Capital raised the firm’s price target on Regeneron to $1,082 from $1,055 and keeps an Outperform rating on the shares after its Q4 earnings beat. Bob Landry’s tenure as CFO at Regeneron sets up the company for another year of growth, with upside coming from Dupixent, inflammation, and oncology drugs, the analyst tells investors in a research note. Regeneron’s ever-increasing cash and marketable securities balance is also giving the company “immense flexibility to transact, expand and return capital to shareholders”, the firm added.